



諾華獲得谷歌 (Google) 的「智慧型隱形眼鏡」技術授權

- 這項創新科技可能對眼部保健產業帶來轉型的機會，並且進一步鞏固愛爾康在隱形眼鏡與人工晶體方面的領導地位
- 這項合約為諾華將科技應用到管理人類疾病和健康情況的第一步

瑞士巴賽爾，2014年7月15日 - 瑞士諾華藥廠 (Novartis) 宣布旗下的眼科保健部門愛爾康 (Alcon) 已與谷歌公司簽署一份合約，將獲得谷歌公司「智慧型隱形眼鏡」技術授權，可運用在各種眼部醫療用途上。這份與谷歌公司旗下專精於為全球重大問題尋找嶄新解決方案之谷歌[x] 實驗室所簽訂的合約，讓愛爾康有機會發展谷歌的「智慧型隱形眼鏡」技術，並將其進行商業化，可能對眼部保健產業帶來轉型的機會，同時進一步鞏固愛爾康在隱形眼鏡與人工水晶體方面的管道和全球領導地位。這項交易仍在進行反托拉斯審理作業。

這份谷歌與愛爾康之間簽訂的合約，代表諾華各部門跨出重要的一步，運用科技來管理人類疾病和健康情況。谷歌在電子零件微型化方面的關鍵優勢，加上諾華在製藥與醫療器材方面深厚的專業技術。諾華的目標為強化找出體內病灶位置的方式，最終則是預防疾病的發生。

諾華執行長吉梅尼茲 (Joe Jimenez) 表示：「我們期待與谷歌合作，結合谷歌先進科技與諾華生技長才來實現過去遙不可及的醫療需求。這次能與谷歌合作是諾華突破傳統疾病管理的一大步，而我們選擇從眼科領域做起。」

谷歌共同創辦人布林 (Sergey Brin) 表示：「我們的夢想就是運用電子裝置微小化方面的最新技術，協助改善數百萬人的生活品質。對於與諾華合作落實這個夢想一事，我們感到十分興奮。」

谷歌[x]與愛爾康基於這份合約，將合作開發有機會解決眼睛健康問題的「智慧型隱形眼鏡」。雙方研發的智慧型隱形眼鏡將內建非侵入性葡萄糖感應器、微晶片及嵌入式微型電子裝置。諾華對此項科技的興趣，目前著重於兩方面：透過「智慧型隱形眼鏡」偵測配戴者淚液中的葡萄糖含量，再將數據傳送到特定行動裝置，以最小侵入程度的方式協助糖尿病患者持續測量體內血糖高低。

而對於必須戴上眼鏡方能閱讀的老花眼患者，戴上「智慧型隱形眼鏡」也能矯正其視力，以適應性隱形眼睛或人工晶體的方式，恢復眼睛自動聚焦在近物上的能力，當成屈光性白內障治療項目之一。

這項合約結合谷歌在微型電子裝置、低功耗晶片設計與微型物品製造方面的專業技術，以及愛爾康在生理學和視力、臨床開發和評估，與隱形眼睛和人工晶體商業化方面的專業知識。藉由這項合作案，愛爾康期望以谷歌的「智慧型隱形眼鏡」技術為基礎，加速推動革新產品。

愛爾康部門主管 Jeff George 表示：「愛爾康與谷歌對於創新一事，均擁有深切一致的熱忱。而愛爾康在眼科保健的領導地位，還有在隱形眼鏡和人工晶體方面專業技術，加上谷歌創新的「智慧型隱形眼鏡」技術與突破性研發速度，我們將成為先鋒，解決全球數百萬名眼部保健患者過去在醫療上未獲滿足的需求。」

Disclaimer

The foregoing release contains forward-looking statements that can be identified by words such as “potential,” “opportunity,” “pipeline,” “subject to anti-trust approvals,” “aims,” “looking forward to,” “will,” “seeks,” “could,” or similar terms, or by express or implied discussions regarding the potential future development of products based on the Google “smart lens” technology, potential additional collaborations between Google and Novartis Group companies, or regarding potential future revenues from such projects. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that products based on the Google “smart lens” technology or any other products based on collaborations between Google and Novartis Group companies will be successfully developed, or approved for sale in any market, or at any particular time. Nor can there be any guarantee that any such products will be commercially successful in the future. In particular, management’s expectations regarding such products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally, including an unexpected failure to obtain necessary government approvals for the collaboration, or unexpected delays in obtaining such approvals; the uncertainties inherent in research and development, including unexpected research failures or delays, unexpected collaboration issues, and unexpected clinical trial results; the company’s ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected manufacturing issues, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this

date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and sell products in more than 150 countries around the world. For more information, please visit <http://www.novartis.com>. Novartis is on Twitter. Sign up to follow @Novartis at <http://twitter.com/novartis>.

About Alcon 愛爾康簡介

愛爾康－全球眼科保健領導者，致力於研發創新產品，以改善民眾視力，從而提升生活品質。愛爾康的業務分為三個領域：眼科手術用品、眼科用藥與視力保健產品 - 提供全球最齊備的眼科保健產品組合。愛爾康是諾華集團旗下的第二大事業體，2013年稅前盈收高達 105 億美元。愛爾康總部位於美國德州沃爾斯堡，全球員工超過 25,000 名、在 75 個國家設有營運據點、產品行銷 180 個國家。更多資訊，請至 www.alcon.com 企業網站。

###

Media Inquiries

Novartis Media Relations

Central media line:

+41 61 324 2200

Eric Althoff

Novartis Global Media Relations

+41 61 324 7999 (direct)

+41 79 593 4202 (mobile)

eric.althoff@novartis.com

Elizabeth Harness Murphy

Alcon Global Media Relations

+1 817 551 8696 (direct)

+1 585 435 7379 (mobile)
elizabeth.murphy@alcon.com

e-mail: media.relations@novartis.com

For Novartis multimedia content, please visit
www.thenewsmarket.com/Novartis

For questions about the site or required registration, please contact:
journalisthelp@thenewsmarket.com

Novartis Investor Relations

Central phone:
+41 61 324 7944

Samir Shah
+41 61 324 7944

Pierre-Michel Bringer
+41 61 324 1065

Thomas Hungerbuehler
+41 61 324 8425

Isabella Zinck
+41 61 324 7188

North America:

Stephen Rubino
+1 862 778 8301

Susan Donofrio
+1 862 778 9257

e-mail: investor.relations@novartis.com